<p>Immunic（纳斯达克股票代码：IMUX - 获取免费报告）可能将在 2026 年 2 月 26 日星期四市场开盘前发布其 2025 年第四季度的财报。分析师预计该公司将在本季度宣布每股收益为（$0.1022）。个人可以访问该公司即将发布的 2025 年第四季度财报页面，以获取有关定于 2026 年 2 月 26 日东部时间上午 9:30 的电话会议的最新信息。</p>
<h2>Immunic 股票下跌 4.4%</h2>
<p>Immunic 股票在星期四以$0.88 开盘。该公司的市值为 1.0551 亿美元，市盈率为-1.06，贝塔值为 1.58。该公司的 50 日移动平均价格为$0.65，200 日移动平均价格为$0.76。Immunic 的 12 个月最低价为$0.51，最高价为$1.39。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近买卖了 IMUX 的股票。Nantahala Capital Management LLC 在第四季度收购了 Immunic 的新股份，价值约为 233.7 万美元。Millennium Management LLC 在第四季度将其在 Immunic 的股份增加了 544.6%。Millennium Management LLC 现在拥有 3,419,299 股该公司的股票，价值 1,825,000 美元，此前在上个季度又收购了 2,888,829 股。Laurion Capital Management LP 在第四季度将其在 Immunic 的持股增加了 106.3%。Laurion Capital Management LP 现在拥有 3,882,162 股该公司的股票，价值 2,072,000 美元，此前在上个季度又购买了 2,000,000 股。Marshall Wace LLP 在第四季度将其在 Immunic 的持股增加了 91.2%。Marshall Wace LLP 现在拥有 1,019,983 股该公司的股票，价值 541,000 美元，此前在此期间又购买了 486,468 股。最后，Squarepoint Ops LLC 在第三季度购买了 Immunic 的新头寸，价值约为 239,000 美元。51.82% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>IMUX 最近成为多份研究报告的主题。D. Boral Capital 在 2026 年 2 月 13 日的报告中将 Immunic 的目标价从$8.00 下调至$4.00，并给予该公司 “买入” 评级。Roth Mkm 在 2026 年 11 月 7 日的研究报告中开始覆盖 Immunic 的股票。他们给予该股票 “买入” 评级，并设定目标价为$3.00。Brookline Capital Acquisition 在 2026 年 2 月 3 日的研究报告中将 Immunic 的股票评级提升至 “强烈买入”。HC Wainwright 在 2026 年 2 月 9 日的研究报告中重申了 “买入” 评级，并设定目标价为$8.00。最后，Chardan Capital 在 2026 年 11 月 19 日的报告中将 Immunic 的股票评级提升至 “强烈买入”。三位股票研究分析师给予该股票 “强烈买入” 评级，五位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Immunic 目前的平均评级为 “买入”，共识目标价为$6.60。</p>
<p><strong>查看我们关于 IMUX 的最新报告</strong></p>
<h2>关于 Immunic</h2>
<p>（获取免费报告）</p>
<p>Immunic, Inc 是一家临床阶段的生物制药公司，专注于开发新型口服疗法，以治疗慢性炎症和自身免疫性疾病以及某些癌症。该公司的研究策略集中在小分子免疫学上，旨在提供具有更好安全性和耐受性特征的靶向治疗。通过调节免疫系统内的关键信号通路，Immunic 旨在解决潜在的疾病机制，并为患者实现持久的治疗效果。</p>
<p>Immunic 的主要产品候选药物 vidofludimus calcium（IMU-838）是一种口服选择性二氢嘧啶脱氢酶（DHODH）抑制剂，目前正在进行针对溃疡性结肠炎、克罗恩病和复发性多发性硬化症等疾病的第二阶段临床开发。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Immunic</li>
<li>你的银行账户不再安全</li>
<li>Nvidia 首席执行官发出大胆的特斯拉预测</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只$15 的股票可能会成为 2026 年的第一只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Immunic 吗？</h2>
<p>在你考虑投资 Immunic 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Immunic 并不在名单上。</p>
<p>虽然 Immunic 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

<p>Immunic (NASDAQ:IMUX) 将于 2 月 26 日发布 2025 年第四季度财报，分析师预测每股亏损 $0.1022。该股目前下跌 4.4%，交易价格为 $0.88，市值为 $1.0551 亿。近期机构活动包括 Nantahala Capital Management 和 Millennium Management 的重大股份收购。分析师对该股的评级不一，普遍目标价为 $6.60。Immunic 专注于开发慢性炎症疾病和癌症的治疗方案，其主要产品正在进行第二阶段临床开发</p>

<p>Immunic (NASDAQ:IMUX - Get Free Report) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.1022) per share for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.</p>
<div class="lb-trans"><p>Immunic（纳斯达克股票代码：IMUX - 获取免费报告）可能将在 2026 年 2 月 26 日星期四市场开盘前发布其 2025 年第四季度的财报。分析师预计该公司将在本季度宣布每股收益为（$0.1022）。个人可以访问该公司即将发布的 2025 年第四季度财报页面，以获取有关定于 2026 年 2 月 26 日东部时间上午 9:30 的电话会议的最新信息。</p>
</div><h2>Immunic Stock Down 4.4%</h2>
<div class="lb-trans"><h2>Immunic 股票下跌 4.4%</h2>
</div><p>Shares of Immunic stock opened at $0.88 on Thursday. The firm has a market cap of $105.51 million, a price-to-earnings ratio of -1.06 and a beta of 1.58. The business has a 50-day moving average price of $0.65 and a 200-day moving average price of $0.76. Immunic has a twelve month low of $0.51 and a twelve month high of $1.39.</p>
<div class="lb-trans"><p>Immunic 股票在星期四以$0.88 开盘。该公司的市值为 1.0551 亿美元，市盈率为-1.06，贝塔值为 1.58。该公司的 50 日移动平均价格为$0.65，200 日移动平均价格为$0.76。Immunic 的 12 个月最低价为$0.51，最高价为$1.39。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of IMUX. Nantahala Capital Management LLC acquired a new stake in shares of Immunic in the fourth quarter valued at about $2,337,000. Millennium Management LLC lifted its stake in Immunic by 544.6% during the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company's stock worth $1,825,000 after acquiring an additional 2,888,829 shares in the last quarter. Laurion Capital Management LP lifted its holdings in Immunic by 106.3% during the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company's stock worth $2,072,000 after buying an additional 2,000,000 shares in the last quarter. Marshall Wace LLP boosted its holdings in Immunic by 91.2% in the fourth quarter. Marshall Wace LLP now owns 1,019,983 shares of the company's stock valued at $541,000 after purchasing an additional 486,468 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in Immunic in the third quarter worth approximately $239,000. 51.82% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买卖了 IMUX 的股票。Nantahala Capital Management LLC 在第四季度收购了 Immunic 的新股份，价值约为 233.7 万美元。Millennium Management LLC 在第四季度将其在 Immunic 的股份增加了 544.6%。Millennium Management LLC 现在拥有 3,419,299 股该公司的股票，价值 1,825,000 美元，此前在上个季度又收购了 2,888,829 股。Laurion Capital Management LP 在第四季度将其在 Immunic 的持股增加了 106.3%。Laurion Capital Management LP 现在拥有 3,882,162 股该公司的股票，价值 2,072,000 美元，此前在上个季度又购买了 2,000,000 股。Marshall Wace LLP 在第四季度将其在 Immunic 的持股增加了 91.2%。Marshall Wace LLP 现在拥有 1,019,983 股该公司的股票，价值 541,000 美元，此前在此期间又购买了 486,468 股。最后，Squarepoint Ops LLC 在第三季度购买了 Immunic 的新头寸，价值约为 239,000 美元。51.82% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>IMUX has been the subject of a number of recent research reports. D. Boral Capital cut their target price on shares of Immunic from $8.00 to $4.00 and set a &#34;buy&#34; rating for the company in a report on Friday, February 13th. Roth Mkm assumed coverage on shares of Immunic in a research note on Friday, November 7th. They issued a &#34;buy&#34; rating and a $3.00 target price on the stock. Brookline Capital Acquisition raised shares of Immunic to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 3rd. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $8.00 target price on shares of Immunic in a research report on Monday, February 9th. Finally, Chardan Capital raised shares of Immunic to a &#34;strong-buy&#34; rating in a report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Immunic presently has an average rating of &#34;Buy&#34; and a consensus price target of $6.60.</p>
<div class="lb-trans"><p>IMUX 最近成为多份研究报告的主题。D. Boral Capital 在 2026 年 2 月 13 日的报告中将 Immunic 的目标价从$8.00 下调至$4.00，并给予该公司 “买入” 评级。Roth Mkm 在 2026 年 11 月 7 日的研究报告中开始覆盖 Immunic 的股票。他们给予该股票 “买入” 评级，并设定目标价为$3.00。Brookline Capital Acquisition 在 2026 年 2 月 3 日的研究报告中将 Immunic 的股票评级提升至 “强烈买入”。HC Wainwright 在 2026 年 2 月 9 日的研究报告中重申了 “买入” 评级，并设定目标价为$8.00。最后，Chardan Capital 在 2026 年 11 月 19 日的报告中将 Immunic 的股票评级提升至 “强烈买入”。三位股票研究分析师给予该股票 “强烈买入” 评级，五位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Immunic 目前的平均评级为 “买入”，共识目标价为$6.60。</p>
</div><p><strong>Check Out Our Latest Report on IMUX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 IMUX 的最新报告</strong></p>
</div><h2>About Immunic</h2>
<div class="lb-trans"><h2>关于 Immunic</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.</p>
<div class="lb-trans"><p>Immunic, Inc 是一家临床阶段的生物制药公司，专注于开发新型口服疗法，以治疗慢性炎症和自身免疫性疾病以及某些癌症。该公司的研究策略集中在小分子免疫学上，旨在提供具有更好安全性和耐受性特征的靶向治疗。通过调节免疫系统内的关键信号通路，Immunic 旨在解决潜在的疾病机制，并为患者实现持久的治疗效果。</p>
</div><p>Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.</p>
<div class="lb-trans"><p>Immunic 的主要产品候选药物 vidofludimus calcium（IMU-838）是一种口服选择性二氢嘧啶脱氢酶（DHODH）抑制剂，目前正在进行针对溃疡性结肠炎、克罗恩病和复发性多发性硬化症等疾病的第二阶段临床开发。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Immunic</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Immunic</li>
<li>你的银行账户不再安全</li>
<li>Nvidia 首席执行官发出大胆的特斯拉预测</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只$15 的股票可能会成为 2026 年的第一只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMUX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunic Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Immunic 吗？</h2>
</div><p>Before you consider Immunic, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Immunic 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Immunic 并不在名单上。</p>
</div><p>While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunic 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immunic (IMUX) 预计将在周四发布季度财报